Matteo Rinaldi1,2, Pier Giorgio Cojutti3,4, Eleonora Zamparini2, Sara Tedeschi1,2, Nicolò Rossi2, Matteo Conti1, Maddalena Giannella1,2, Federico Pea5,2, Pierluigi Viale1,2. 1. Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Italy. 2. Infectious Diseases Unit, University Hospital IRCCS Policlinico Sant'Orsola, Bologna, Italy. 3. Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital of Udine, ASUFC, Udine, Italy. 4. Department of Medicine, University of Udine, Italy. 5. Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Italy federico.pea@unibo.it.
Abstract
Background: Fosfomycin is gaining interest in the treatment of complex osteoarticular infections (OI) due to MDR pathogens.Objective: The aims were to conduct population pharmacokinetics of fosfomycin in a cohort of OI patients receiving 16g/daily by intermittent (II) or continuous infusion (CI), and to carry out Monte Carlo simulations for dosage optimization in the treatment of these infections. Methods: Patients underwent blood sampling on day 5 of therapy (2-3 serial samples). Population pharmacokinetics and Monte Carlo simulations were performed to define the probability of target attainment (PTA) of 70% T>MIC, and the cumulative fraction of response (CFR) against common OI pathogens with dosages of 8, 12, 16, and 20g/day administered by II, extended-infusion (EI) or CI. Results: Forty-eight patients were recruited. A two-compartment open model with infusion input and first-order elimination was developed. Estimated creatinine clearance (CLCR) was included as covariate in the final model. Monte Carlo simulations showed that optimal PTAs and CFRs (≥90%) may be achieved in three different classes of renal function by administering a daily dosage of: 2g q6h by II against S. aureus, E. coli, ESBL-producing E. Coli and MRSA; 8g by CI against CoNS, K. pneumoniae and ESBL-producing K. pneumoniae; 12g by CI against P. aeruginosa, and 16g by CI against KPC-producing K. pneumoniae Conclusion: Our study provides a strong rationale for considering fosfomycin dosages of 8-16 g daily by CI in several clinical scenarios for OI patients. Feasibility of administration by CI in an elastomeric pump makes fosfomycin a candidate for OPAT programs.
Background: Fosfomycin is gaining interest in the treatment of complex osteoarticular infections (OI) due to MDR pathogens.Objective: The aims were to conduct population pharmacokinetics of fosfomycin in a cohort of OI patients receiving 16g/daily by intermittent (II) or continuous infusion (CI), and to carry out Monte Carlo simulations for dosage optimization in the treatment of these infections. Methods:Patients underwent blood sampling on day 5 of therapy (2-3 serial samples). Population pharmacokinetics and Monte Carlo simulations were performed to define the probability of target attainment (PTA) of 70% T>MIC, and the cumulative fraction of response (CFR) against common OI pathogens with dosages of 8, 12, 16, and 20g/day administered by II, extended-infusion (EI) or CI. Results: Forty-eight patients were recruited. A two-compartment open model with infusion input and first-order elimination was developed. Estimated creatinine clearance (CLCR) was included as covariate in the final model. Monte Carlo simulations showed that optimal PTAs and CFRs (≥90%) may be achieved in three different classes of renal function by administering a daily dosage of: 2g q6h by II against S. aureus, E. coli, ESBL-producing E. Coli and MRSA; 8g by CI against CoNS, K. pneumoniae and ESBL-producing K. pneumoniae; 12g by CI against P. aeruginosa, and 16g by CI against KPC-producing K. pneumoniae Conclusion: Our study provides a strong rationale for considering fosfomycin dosages of 8-16 g daily by CI in several clinical scenarios for OI patients. Feasibility of administration by CI in an elastomeric pump makes fosfomycin a candidate for OPAT programs.
Authors: Michael N Neely; Michael G van Guilder; Walter M Yamada; Alan Schumitzky; Roger W Jelliffe Journal: Ther Drug Monit Date: 2012-08 Impact factor: 3.681
Authors: Clare C Walsh; Michelle P McIntosh; Anton Y Peleg; Carl M Kirkpatrick; Phillip J Bergen Journal: J Antimicrob Chemother Date: 2015-07-24 Impact factor: 5.790
Authors: Alexander J Lepak; Miao Zhao; Brian VanScoy; Daniel S Taylor; Evelyn Ellis-Grosse; Paul G Ambrose; David R Andes Journal: Antimicrob Agents Chemother Date: 2017-05-24 Impact factor: 5.191
Authors: Arnold Louie; Michael Maynard; Brandon Duncanson; Jocelyn Nole; Michael Vicchiarelli; G L Drusano Journal: Antimicrob Agents Chemother Date: 2018-05-25 Impact factor: 5.191
Authors: Anneke Corinne Dijkmans; Natalia Veneranda Ortiz Zacarías; Jacobus Burggraaf; Johan Willem Mouton; Erik Bert Wilms; Cees van Nieuwkoop; Daniel Johannes Touw; Jasper Stevens; Ingrid Maria Catharina Kamerling Journal: Antibiotics (Basel) Date: 2017-10-31
Authors: D Busse; P Simon; D Petroff; N El-Najjar; L Schmitt; D Bindellini; A Dietrich; M Zeitlinger; W Huisinga; R Michelet; H Wrigge; C Kloft Journal: Antimicrob Agents Chemother Date: 2022-05-23 Impact factor: 5.938